Clinical Trials Browser

bicalutamide × Genitourinary × Clear all

NCT07593079 2026-05-18

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT00544830 2026-05-15

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Active not recruiting

29 enrolled 12 charts

PSA Level Greater Than Two

NCT07455903 2026-05-13

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Phase 2 Recruiting

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03070886 2026-05-07

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

Stage I Prostate Adenocarcinoma AJCC v7

NCT05521698 2026-05-05

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Non-Muscle Invasive Bladder Urothelial Carcinoma

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Phase 3 Active not recruiting

Prostate Adenocarcinoma

NCT01251861 2026-04-29

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Phase 2 Active not recruiting

108 enrolled 16 charts

Prostatic Neoplasms

NCT02346253 2026-04-13

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Phase NA Active not recruiting

Prostatic Neoplasms

NCT04787744 2026-04-08

VA STARPORT

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Phase 3 Completed

1,538 enrolled 37 charts

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT04943536 2026-02-27

BiolenRT

Phase 1 Active not recruiting

Prostate Adenocarcinoma

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07393867 2026-02-06

ARPEGGIO

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT01809691 2025-12-31

S1216

Phase 3 Completed

1,313 enrolled 22 charts

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT03009981 2025-12-18

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT05327647 2025-12-18

BicaBCa

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT03348670 2025-08-17

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT01342367 2025-06-10

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Phase NA Active not recruiting

74 enrolled 12 charts

Prostatic Neoplasms

NCT00328614 2025-05-16

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Phase 1 Completed

32 enrolled 12 charts

Prostatic Neoplasms

NCT01420250 2025-05-15

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT00223145 2025-01-27

PCS III

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT01288911 2024-12-06

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Phase 2 Completed

375 enrolled 24 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT02366494 2024-11-25

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03358563 2024-05-03

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06018116 2024-02-15

CANUCK-01

Phase 2 Withdrawn

Carcinoma, Transitional Cell

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00482807 2023-11-24

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00541047 2023-11-13

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

Phase 3 Completed

GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

NCT00651326 2023-08-04

DART

Phase 3 Terminated

Prostatic Neoplasms

NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Phase 2 Completed

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

NCT00771017 2023-05-25

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT02058706 2023-05-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 2 Completed

71 enrolled 18 charts

Prostatic Neoplasms

NCT05019846 2023-04-18

SPA

Phase 3 Recruiting

Prostatic Neoplasms

NCT03043807 2023-02-16

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2 Completed

26 enrolled 8 charts

Prostatic Neoplasms

NCT00055731 2023-01-18

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase 3 Completed

Prostatic Neoplasms